A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age
Status:
Terminated
Trial end date:
2016-08-03
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, efficacy, and pharmacokinetic and
pharmacodynamic activity of 3 different dosages of RO5186582 compared with placebo. A total
of approximately 46 participants will be enrolled, in order to have at least 32 evaluable,
and will be randomly assigned to 1 of 4 treatments in a 1:1:1:1 ratio, with 9 children per
treatment arm. The target ratio between 6-8 years and 9-11 years age groups is approximately
1:1 in each treatment arm, with a minimum of 3 children per age group in each treatment arm.